Preventing Alzheimer's Disease

    Research output: Chapter in Book/Report/Conference proceedingChapter

    1 Citation (Scopus)

    Abstract

    Current drug treatments for Alzheimer's disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of ß-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive trials have been completed but so far none has demonstrated significant benefits and some were potentially harmful. New preclinical treatment trials are underway in people at the highest risk of developing AD in the following few years. A US National Institutes of Health panel found no evidence of even moderate scientific quality to clearly support the association of any modifiable factors with a reduced risk of cognitive decline or AD. The best current evidence suggests that heart-healthy eating patterns such as the Mediterranean diet may help to protect the brain. Future preventive approaches will need to harness the increased technological advances concerning biomarkers with new hypotheses driven by a better understanding of the relevant risk factors.
    Original languageEnglish
    Title of host publicationGlobal Clinical Trials for Alzheimer's Disease
    Subtitle of host publicationDesign, Implementation, and Standardization
    Pages33-46
    Number of pages14
    DOIs
    Publication statusPublished - 1 Sep 2013

    Fingerprint

    Alzheimer Disease
    Amyloid
    Biomarkers
    Mediterranean Diet
    National Institutes of Health (U.S.)
    Neuroimaging
    Cerebrospinal Fluid
    Therapeutics
    Brain
    Pharmaceutical Preparations
    Cognitive Dysfunction

    Cite this

    Jones, R. W. (2013). Preventing Alzheimer's Disease. In Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization (pp. 33-46) https://doi.org/10.1016/B978-0-12-411464-7.00003-1

    Preventing Alzheimer's Disease. / Jones, R.W.

    Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization. 2013. p. 33-46.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Jones, RW 2013, Preventing Alzheimer's Disease. in Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization. pp. 33-46. https://doi.org/10.1016/B978-0-12-411464-7.00003-1
    Jones RW. Preventing Alzheimer's Disease. In Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization. 2013. p. 33-46 https://doi.org/10.1016/B978-0-12-411464-7.00003-1
    Jones, R.W. / Preventing Alzheimer's Disease. Global Clinical Trials for Alzheimer's Disease: Design, Implementation, and Standardization. 2013. pp. 33-46
    @inbook{33193fca44aa430280b56703ac8b54a8,
    title = "Preventing Alzheimer's Disease",
    abstract = "Current drug treatments for Alzheimer's disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of {\ss}-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive trials have been completed but so far none has demonstrated significant benefits and some were potentially harmful. New preclinical treatment trials are underway in people at the highest risk of developing AD in the following few years. A US National Institutes of Health panel found no evidence of even moderate scientific quality to clearly support the association of any modifiable factors with a reduced risk of cognitive decline or AD. The best current evidence suggests that heart-healthy eating patterns such as the Mediterranean diet may help to protect the brain. Future preventive approaches will need to harness the increased technological advances concerning biomarkers with new hypotheses driven by a better understanding of the relevant risk factors.",
    author = "R.W. Jones",
    year = "2013",
    month = "9",
    day = "1",
    doi = "10.1016/B978-0-12-411464-7.00003-1",
    language = "English",
    isbn = "9780124114647",
    pages = "33--46",
    booktitle = "Global Clinical Trials for Alzheimer's Disease",

    }

    TY - CHAP

    T1 - Preventing Alzheimer's Disease

    AU - Jones, R.W.

    PY - 2013/9/1

    Y1 - 2013/9/1

    N2 - Current drug treatments for Alzheimer's disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of ß-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive trials have been completed but so far none has demonstrated significant benefits and some were potentially harmful. New preclinical treatment trials are underway in people at the highest risk of developing AD in the following few years. A US National Institutes of Health panel found no evidence of even moderate scientific quality to clearly support the association of any modifiable factors with a reduced risk of cognitive decline or AD. The best current evidence suggests that heart-healthy eating patterns such as the Mediterranean diet may help to protect the brain. Future preventive approaches will need to harness the increased technological advances concerning biomarkers with new hypotheses driven by a better understanding of the relevant risk factors.

    AB - Current drug treatments for Alzheimer's disease (AD) appear to be symptomatic. There is an increasing priority to find effective and safe disease-modifying and preventive treatment strategies for cognitive decline, AD, and dementia. Recent developments have allowed the identification of possible pathogenic processes and pathways, and potential targets for intervention. Cerebrospinal fluid (CSF) biomarkers of ß-amyloid and tau, and neuroimaging including amyloid PET tracer retention show that the pathogenic process begins many years before symptoms appear. A number of preventive trials have been completed but so far none has demonstrated significant benefits and some were potentially harmful. New preclinical treatment trials are underway in people at the highest risk of developing AD in the following few years. A US National Institutes of Health panel found no evidence of even moderate scientific quality to clearly support the association of any modifiable factors with a reduced risk of cognitive decline or AD. The best current evidence suggests that heart-healthy eating patterns such as the Mediterranean diet may help to protect the brain. Future preventive approaches will need to harness the increased technological advances concerning biomarkers with new hypotheses driven by a better understanding of the relevant risk factors.

    UR - http://www.scopus.com/inward/record.url?scp=84903866370&partnerID=8YFLogxK

    UR - http://dx.doi.org/10.1016/B978-0-12-411464-7.00003-1

    U2 - 10.1016/B978-0-12-411464-7.00003-1

    DO - 10.1016/B978-0-12-411464-7.00003-1

    M3 - Chapter

    SN - 9780124114647

    SP - 33

    EP - 46

    BT - Global Clinical Trials for Alzheimer's Disease

    ER -